ANSM updates medicinal product directory

The National Agency for Medicinal Product Safety and Health Products (ANSM) has updated its Generic Groups Directory, a classification system used to organize medications by their active ingredients and dosages, through a decision made on October 22, 2026. This update includes the creation of new groups and modifications to existing ones, primarily involving five active substances with specific dosage forms.

New groups for acetylcysteine

The update introduces a new group for acetylcysteine, which includes two products: Mucomyst 200 mg, a powder for oral solution in a sachet, and Acetylcysteine Medipha Santé 200 mg, granules in a sachet. These formulations are used for conditions such as mucous congestion or as an antidote for acetaminophen overdose.

Prednisolone added to existing group

A new product, Prednisolone Arrow Lab 5 mg, has been added to a group that previously included Solupred 5 mg, an orally disintegrating tablet. This group represents different formulations of prednisolone, a corticosteroid used for inflammation and immune-related conditions.

Progesterone group includes new formulation

The progesterone group now includes Phasella 25 mg, a new product, alongside Progiron 25 mg, an injectable solution used for intramuscular and subcutaneous administration. Progesterone is a hormone used in reproductive health and certain hormonal therapies.

Multiple groups for ruxolitinib

Four separate groups have been created for ruxolitinib, a medication used in treating certain blood cancers. These groups are based on different dosages of Jakavi, the brand name for ruxolitinib, including 5, 10, 15, and 20 mg. The products involved are Ruxolitinib Olpha and Ruxolitinib Sandoz.

Tofacitinib groups combine two brands

Two groups have been formed for tofacitinib, another drug used in autoimmune conditions. These groups bring together Xeljanz and Tofacitinib Stada, both available in film-coated tablets at 5 mg and 10 mg dosages, respectively.